Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C22H27NO2.H2O4S |
| Molecular Weight | 772.989 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CN1[C@H](C[C@H](O)C2=CC=CC=C2)CCC[C@@H]1CC(=O)C3=CC=CC=C3.CN4[C@H](C[C@H](O)C5=CC=CC=C5)CCC[C@@H]4CC(=O)C6=CC=CC=C6
InChI
InChIKey=GRZMOSSVIPFGFF-GNJLJDPWSA-N
InChI=1S/2C22H27NO2.H2O4S/c2*1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18;1-5(2,3)4/h2*2-7,9-12,19-21,24H,8,13-16H2,1H3;(H2,1,2,3,4)/t2*19-,20+,21-;/m00./s1
| Molecular Formula | C22H27NO2 |
| Molecular Weight | 337.4553 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/npp/lobelia.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12875893 | https://www.ncbi.nlm.nih.gov/pubmed/12604705 | https://clinicaltrials.gov/ct2/show/record/NCT00664703 | https://clinicaltrials.gov/ct2/show/study/NCT00519259
Sources: https://www.drugs.com/npp/lobelia.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12875893 | https://www.ncbi.nlm.nih.gov/pubmed/12604705 | https://clinicaltrials.gov/ct2/show/record/NCT00664703 | https://clinicaltrials.gov/ct2/show/study/NCT00519259
Lobeline is an alkaloid found in "Indian tobacco" (Lobelia inflata), "Devil's tobacco" (Lobelia tupa), "cardinal flower" (Lobelia cardinalis), "great lobelia" (Lobelia siphilitica), and Hippobroma longiflora. Additionally, it is also found in Lobelia Chinensis. In its pure form, it is a white amorphous powder which is freely soluble in water. Lobeline has been sold, in tablet form, for use as a smoking cessation aid, and may have application in the treatment of other drug addictions such as addiction to amphetamines, cocaine, or alcohol. Lobeline has multiple mechanisms of action, acting as a VMAT2 ligand, which stimulates dopamine release to a moderate extent when administered alone, but reduces the dopamine release caused by methamphetamine. It also inhibits the reuptake of dopamine and serotonin and acts as a mixed agonist-antagonist at nicotinic acetylcholine receptors to which it binds at the subunit interfaces of the extracellular domain. It is also an antagonist at μ-opioid receptors. It seems to be a P-glycoprotein inhibitor, according to at least one study. It has been hypothesized that P-glycoprotein inhibition reduces chemotherapeutic resistance in cancer, presumably affecting any substrates of P-gp.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12875893
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/12604705
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4828 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19691331 |
470.0 nM [Ki] | ||
Target ID: CHEMBL1907589 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26142318 |
4.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.008 g 4 times / day multiple, oral Studied dose Dose: 0.008 g, 4 times / day Route: oral Route: multiple Dose: 0.008 g, 4 times / day Sources: |
healthy, 28 years Health Status: healthy Age Group: 28 years Sex: M Sources: |
|
59 ug/kg single, intravenous Highest studied dose Dose: 59 ug/kg Route: intravenous Route: single Dose: 59 ug/kg Sources: |
unhealthy, 45 years |
Other AEs: Cough... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cough | 59 ug/kg single, intravenous Highest studied dose Dose: 59 ug/kg Route: intravenous Route: single Dose: 59 ug/kg Sources: |
unhealthy, 45 years |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/18222670/ Page: 3.0 |
no | |||
Page: 15.0 |
yes [IC50 0.12 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18222670/ Page: 3.0 |
yes [Inhibition 20 uM] |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/20734202/ Page: 1.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones. | 2010-04-21 |
|
| (2S,6S)-1-Methyl-2,6-trans-distyryl-piperidinium chloride. | 2009-12-09 |
|
| 1-Methyl-2,6-cis-distyrylpiperidine. | 2009-12-09 |
|
| Synthesis of (-)-lobeline via enzymatic desymmetrization of lobelanidine. | 2009-03-01 |
|
| Pd-catalyzed enantioselective aerobic oxidation of secondary alcohols: applications to the total synthesis of alkaloids. | 2008-10-15 |
|
| The exceptional hydrogen-bond properties of neutral and protonated lobeline. | 2007-07-19 |
|
| Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. | 2007-07-10 |
|
| Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors. | 2006-10-01 |
|
| Indirect trapping of the retroconjugate addition reaction intermediate involved in the epimerization of lobeline: application to the synthesis of (-)-sedamine. | 2004-11-26 |
|
| A specific anti-aggressive effect of repeatedly administered lobeline. | 2002-07 |
|
| The variability and repeatability of indices derived from the single-breath diagram for CO2 in horses with chronic obstructive pulmonary disease and the effect of lobelin hydrochloride on these indices. | 2001-07 |
|
| A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception. | 2001-04 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npp/lobelia.html
linical studies of lobeline for smoking withdrawal administered doses of 5 mg twice a day, with 0.5 mg lozenges used in addition when the urge to smoke was perceived
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19691331
Inhibition of [3H]-DA uptake was conducted in a preparation of isolated synaptic vesicles rat striata were homogenized with 10 strokes of a Teflon pestle homogenizer in 14 ml of 0.32 M sucrose solution. Homogenate was centrifuged (, and the resulting supernatant was centrifuged again). The pellet was resuspended in 2 ml of 0.32 M sucrose solution and subjected to osmotic shock by adding 7 ml of ice-cold water to the preparation, followed by the immediate restoration of osmolarity by adding 900 mkl of 0.25M HEPES buffer and 900 mkl of 1.0 M potassium tartrate solution. Samples were centrifuged, and the resulting supernatant was centrifuged again, followed by the addition of 100 mkl of 10 mM MgSO4, 100 mkl of 0.25 M HEPES and 100 mkl of 1.0 M potassium tartrate solution prior to the final centrifugation. The final pellet was resuspended in 2.4 ml of assay buffer. Aliquots of the vesicular suspension were added to tubes containing assay buffer, various concentrations of Lobeline (0.1 nM – 10 mM) and 0.1 PM [3H]-DA in a final volume of 500 Pl. Nonspecific uptake was determined in the presence of Ro4-1284 (10 mkM). Reactions were terminated by filtration, and radioactivity retained by the filters was determined by liquid scintillation spectroscopy
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:02 GMT 2025
by
admin
on
Mon Mar 31 17:54:02 GMT 2025
|
| Record UNII |
4CJ480V2HP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 310.544
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB02962MIG
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
205-151-8
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
100000086131
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
m6879
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID80158452
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
4CJ480V2HP
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
120636
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY | |||
|
134-64-5
Created by
admin on Mon Mar 31 17:54:02 GMT 2025 , Edited by admin on Mon Mar 31 17:54:02 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |